Emergent BioSolutions (EBS) IPO Opens for Trading
Tweet Send to a FriendGet Alerts EBS Hot Sheet
Up)
Trade EBS Now!
The IPO for Emergent BioSolutions Inc. (NYSE: EBS) is open for trading. The stock is trading at $12.26 after pricing 5,000,000 shares at $12.50 per share, the low end of the expected $14-$16 range.
J.P. Morgan Securities Inc. acted as sole book-running manager for the offering with Cowen and Company, LLC as joint lead manager and HSBC Securities (USA) Inc. as co-manager. The offering is expected to close on November 20, 2006, subject to the satisfaction of customary closing conditions.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics, such as vaccines and immune globulins, which induce or
assist the body's immune system to prevent or treat disease. Emergent's biodefense business is focused on developing and commercializing immunobiotics for use against biological agents that
are potential weapons of bioterrorism. The Company's commercial business is focused on developing immunobiotics for use against infectious diseases with significant unmet or underserved medical
needs.
J.P. Morgan Securities Inc. acted as sole book-running manager for the offering with Cowen and Company, LLC as joint lead manager and HSBC Securities (USA) Inc. as co-manager. The offering is expected to close on November 20, 2006, subject to the satisfaction of customary closing conditions.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics, such as vaccines and immune globulins, which induce or
assist the body's immune system to prevent or treat disease. Emergent's biodefense business is focused on developing and commercializing immunobiotics for use against biological agents that
are potential weapons of bioterrorism. The Company's commercial business is focused on developing immunobiotics for use against infectious diseases with significant unmet or underserved medical
needs.
You May Also Be Interested In
- Emergent BioSolutions to Webcast Presentation at Jefferies 2013 Global Healthcare Conference
- Gene Therapy Company bluebird bio (BLUE) Files $86M IPO
- Marketo (MKTO) IPO Opens 54% Higher
Create E-mail Alert Related Categories
IPOs
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
